



L Number	Hits	Search Text	DB	Time stamp
1	387	536/17.4	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 09:55
2	4	536/17.4 and azetidinone	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 09:56
3	2381	514/23	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 09:56
4	9	514/23 and azetidinone	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 10:02
5	133	514/210.02	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 10:03
6	62	514/210.02 and azetidinone	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 10:03



```

chain nodes :
 5 18 19 20 22
ring nodes :
 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 21 23 24 25 26 27
chain bonds :
 1-12 2-5 3-18 4-6 18-19 19-20 20-21 20-22
ring bonds :
 1-2 1-4 2-3 3-4 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16
 16-17 21-23 21-27 23-24 24-25 25-26 26-27
exact/norm bonds :
 1-2 1-4 1-12 2-3 2-5 3-4 20-22
exact bonds :
 3-18 4-6 18-19 19-20 20-21
normalized bonds :
 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 21-23 21-27
 23-24 24-25 25-26 26-27

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS
 21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 AUG 22 Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31 AUG 15 PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32 AUG 15 PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34 AUG 15 TEMA: one FREE connect hour, per account, in September 2003
NEWS 35 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 36 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 37 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:50:17 ON 07 SEP 2003

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 07 SEP 2003 --
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2003 HIGHEST RN 580198-40-9
DICTIONARY FILE UPDATES: 5 SEP 2003 HIGHEST RN 580198-40-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See **HELP CROSSOVER** for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10021502-1.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam - - - - -
SAMPLE SEARCH INITIATED 10:50:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 173 TO 747
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN D-glycero-D-gulo-Heptitol, 2,6-anhydro-1-O-[3-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl]-2-propenyl]-(9CI)
MF C34 H37 F2 N O8

Absolute stereochemistry.
Double bond geometry unknown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
 IN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-[4-[3-[[6-[[3',6'-
 dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-
 yl]carbonyl]amino]-1-oxohexyl]amino]-1-propynyl]phenyl]-3-[(3S)-3-(4-
 fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI)
 MF C60 H54 F N3 O16

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s 11 sss full
FULL SEARCH INITIATED 10:51:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -----488-TO-ITERATE-----
```

```
100.0% PROCESSED      488 ITERATIONS          218 ANSWERS
SEARCH TIME: 00.00.01
```

L3 218 SEA SSS FUL L1

| | | |
|----------------------|------------|---------|
| => file caplus | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 148.95 | 149.16 |

```
FILE 'CAPLUS' ENTERED AT 10:52:15 ON 07 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2003 VOL 139 ISS 11
FILE LAST UPDATED: 5 Sep 2003 (20030905/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 and composition
 110 L3
 606547 COMPOSITION
 263931 COMPOSITIONS
 865452 COMPOSITION
 (COMPOSITION OR COMPOSITIONS)
 1242948 COMPN
 494645 COMPNS
 1519862 COMPN
 (COMPN OR COMPNS)
 1951035 COMPOSITION
 (COMPOSITION OR COMPN)
 L4 16 L3 AND COMPOSITION

=> s 14 and (antidiabetic or HMG or PPAR)
 12384 ANTIDIABETIC
 4862 ANTIDIABETICS
 14982 ANTIDIABETIC
 (ANTIDIABETIC OR ANTIDIABETICS)
 7950 HMG
 93 HMGS
 7970 HMG
 (HMG OR HMGS)
 3697 PPAR
 534 PPARS
 3762 PPAR
 (PPAR OR PPARS)
 L5 9 L4 AND (ANTIDIABETIC OR HMG OR PPAR)

- - - - -=> dis 14 1-16 bib abs hitstr

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:633275 CAPLUS
 DN 139:169333
 TI Novel anticholesterol compositions and method for using same
 IN Dudley, Robert; Liao, Shutsung; Song, Ching
 PA USA
 SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 8

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | US 2003153541 | A1 | 20030814 | US 2002-174934 | 20020619 |
| | WO 9922728 | A1 | 19990514 | WO 1998-US23041 | 19981030 |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 6576660 | B1 | 20030610 | US 2000-530443 | 20000428 |
| | US 2002107233 | A1 | 20020808 | US 2002-72128 | 20020208 |
| | US 2002193357 | A1 | 20021219 | US 2002-137695 | 20020502 |
| PRAI | US 1997-63770P | P | 19971031 | | |
| | WO 1998-US23041 | W | 19981030 | | |
| | US 1999-131728P | P | 19990430 | | |
| | US 2000-530443 | A2 | 20000428 | | |
| | US 2000-560236 | A2 | 20000428 | | |
| | US 2001-267493P | P | 20010208 | | |
| | US 2001-288643P | P | 20010503 | | |

US 2001-348020P P 20011108
 US 2002-72128 A2 20020208
 US 2002-137695 A2 20020502

AB Disclosed are compns., methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concn., for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The compns., methods, combinations, and kits of the present invention are pharmaceutical compns. comprising at least two of an LXR receptor modulator, a therapeutically effective amt. of a catechin, and/or a therapeutically effective amt. of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid deriv., niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3 fatty acid.


IT 163222-33-1, Ezetimibe

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anticholesterol compns. contg. LXR modulators and lipid regulating agents)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:511859 CAPLUS

DN 139:90459

TI Use of an immediate-release powder in pharmaceutical and nutraceutical compositions

IN Besse, Jerome; Besse, Laurence

PA Fr.

SO U.S. Pat. Appl. Publ., 5 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---------------|------|----------|-----------------|----------|
| PI | US 2003124191 | A1 | 20030703 | US 2002-106923 | 20020325 |
| | FR 2834212 | A1 | 20030704 | FR 2001-16934 | 20011227 |
| | WO 2003055464 | A1 | 20030710 | WO 2002-FR4575 | 20021227 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, | | | | | |

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRAI FR 2001-16934 A 20011227

AB The present invention relates to the use of a powder comprising at least one active substance, at least one surfactant, at least one wetting agent and at least one diluent, for prep. a pharmaceutical or nutraceutical compn., this compn. allowing rapid and immediate release of the active substance. Granules contg. phloroglucinol 10, sorbitol 89, and propylene glycol 1% were prep'd.


IT 163222-33-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of immediate-release powder in pharmaceutical and nutraceutical compns.)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:492702 CAPLUS

DN 139:47580

TI Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women

IN Strony, John T.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2003119796 | A1 | 20030626 | US 2002-247085 | 20020919 |
| | US 2003105028 | A1 | 20030605 | US 2002-166942 | 20020611 |
| PRAI | US 2001-324118P | P | 20010921 | | |
| | US 2002-166942 | A2 | 20020611 | | |
| | US 2000-256875P | P | 20001220 | | |
| | US 2001-23295 | A2 | 20011217 | | |

OS MARPAT 139:47580

AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one hormone replacement therapy compn.; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5.alpha.-stanols.

IT 163222-32-0P 163222-33-1P 163380-15-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of sterol absorption inhibitors for the combined use with hormone replacement therapy compns. and treatments for vascular conditions in post-menopausal women)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:492667 CAPLUS

DN 139:57965

TI Methods and therapeutic combinations for the treatment of obesity using

sterol absorption inhibitors
 IN Davis, Harry R.; Ress, Rudyard J.; Strony, John T.; Veltri, Enrico P.
 PA Schering Corporation, USA
 SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 166,942.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2003119428 | A1 | 20030626 | US 2002-247397 | 20020919 |
| | US 2003105028 | A1 | 20030605 | US 2002-166942 | 20020611 |
| PRAI | US 2001-323840P | P | 20010921 | | |
| | US 2002-166942 | A2 | 20020611 | | |
| | US 2000-256875P | P | 20001220 | | |
| | US 2001-23295 | A2 | 20011217 | | |

OS MARPAT 139:57965

AB The present invention provides methods for the treatment of obesity using sterol or 5.alpha.-stanol absorption inhibitors and compns. and therapeutic combinations including sterol or 5.alpha.-stanol absorption inhibitors and at least one obesity control medication. Prepn. of azetidinone derivs. is described. A tablet contained active compd. 102, lactose monohydrate 553, microcryst. cellulose 204, povidone (K29-32) 45, croscarmellose sodium 86, sodium lauryl sulfate 27, and magnesium stearate 1 mg.

IT 163222-33-1P 163380-16-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods and therapeutic combinations for treatment of obesity using sterol absorption inhibitors)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 163380-16-3 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 163222-32-0P 163380-15-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods and therapeutic combinations for treatment of obesity using sterol absorption inhibitors)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:435299 CAPLUS

DN 139:22062

TI Preparation of substituted 2-azetidinones and use as hypocholesterolemic agents

IN Ghosal, Anima; Zbaida, Shmuel; Chowdhury, Swapan K.; Iannucci, Robert M.; Feng, Wenqing; Alton, Kevin B.; Patrick, James E.; Davis, Harry R.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 23,295.




CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|----------|
| PI | US 2003105028 | A1 | 20030605 | US 2002-166942 | 20020611 |
| | US 2002137690 | A1 | 20020926 | US 2001-23295 | 20011217 |
| | US 2003119757 | A1 | 20030626 | US 2002-247032 | 20020919 |
| | US 2003119796 | A1 | 20030626 | US 2002-247085 | 20020919 |
| | US 2003119428 | A1 | 20030626 | US 2002-247397 | 20020919 |
| PRAI | US 2000-256875P | P | 20001220 | | |
| | US 2001-23295 | A2 | 20011217 | | |
| | US 2001-323840P | P | 20010921 | | |
| | US 2001-323937P | P | 20010921 | | |
| | US 2001-324118P | P | 20010921 | | |
| | US 2002-166942 | A2 | 20020611 | | |
| OS | MARPAT 139:22062 | | | | |
| GI | | | | | |



AB The authors report the prepn. of substituted 2-azetidinone compds. I [R1 = H, SO₃H, Q1, etc., R3, R4, R5 = H, C₁-C₆ alkyl, CO-aryl, etc., R6 = H, C₁-C₆ alkyl, COMe, etc., R8 = H, alkyl, R26 = H, OH, F, etc., Ar1 = aryl, heteroaryl, etc., Ar2 = aryl, heteroaryl, etc., L = covalent bond, CO, phenylene, etc., Q = (CH₂)_n, n = 2-6, spiro group, etc.], as well as methods of lowering cholesterol by administering said compds., pharmaceutical compns. contg. them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis. Thus, 14C-Sch 58235 was converted to the benzylic glucuronide II using UDPGA (uridine diphosphoglucuronosyltransferase) as catalyst.

IT 163222-33-1P, Sch 58235

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 190448-57-8, Sch 60663

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(prepn. of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 190448-57-8 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 438576-93-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 438576-93-3 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, labeled with carbon-14, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:868252 CAPLUS

DN 138:348551

TI Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte

AU Repa, Joyce J.; Dietschy, John M.; Turley, Stephen D.

CS Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA

SO Journal of Lipid Research (2002), 43(11), 1864-1874

CODEN: JLPRAW; ISSN: 0022-2275

PB Lipid Research, Inc.

DT Journal

LA English

AB Intestinal cholesterol absorption is a major determinant of plasma low d. lipoprotein-cholesterol (LDL-C) concns. Ezetimibe (SCH 58235) and its analogs SCH 48461 and SCH 58053 are novel potent inhibitors of cholesterol absorption whose mechanism of action is unknown. These studies investigated the effect of SCH 58053 on cholesterol metab. in female 129/Sv mice. In mice fed a low cholesterol rodent diet contg. SCH 58053, cholesterol absorption was reduced by 46% and fecal neutral sterol excretion was increased 67%, but biliary lipid compn. and bile acid synthesis, pool size, and pool compn. were unchanged. When the dietary cholesterol content was increased either 10- or 50-fold, those animals given SCH 58053 manifested lower hepatic and biliary cholesterol concns. than did their untreated controls. Cholesterol feeding increased the relative mRNA level for ATP-binding cassette transporter A1 (ABCA1), ABC transporter G5 (ABCG5), and ABC transporter G8 (ABCG8) in the jejunum, and of ABCG5 and ABCG8 in the liver, but the magnitude of this increase was generally less if the mice were given SCH 58053. We conclude that the inhibition of cholesterol absorption effected by this new class of agents is not mediated via changes in either the size or compn. of the intestinal bile acid pool, or the level of mRNA expression of proteins that facilitate cholesterol efflux from the enterocyte, but rather may involve disruption of the uptake of luminal sterol across the microvillus membrane.

IT 163222-33-1, Ezetimibe


RL: DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:716094 CAPLUS
 DN 137:226612
 TI Antihypertensive agent and cholesterol absorption inhibitor combination therapy
 IN Nichtberger, Steven A.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2002072104 | A2 | 20020919 | WO 2002-US6570 | 20020305 |
| | WO 2002072104 | A3 | 20030724 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 2001-274288P | P | 20010308 | | |
| AB | The invention includes methods for treating atherosclerosis and preventing atherosclerotic disease events in a hypertensive patient comprising administering to the patient a therapeutically or prophylactically effective amt. of at least one antihypertensive compd. in combination with a therapeutically effective amt. of a cholesterol absorption inhibitor. The invention also includes a compn. comprising at least one antihypertensive compd. and a cholesterol absorption inhibitor in therapeutically effective amts., and a pharmaceutically acceptable carrier. | | | | |
| IT | 163222-33-1, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antihypertensive agent and cholesterol absorption inhibitor combination therapy) | | | | |
| RN | 163222-33-1 CAPLUS | | | | |
| CN | 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-(3R,4S)-(9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry. Rotation (-).



L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:575765 CAPLUS
 DN 137:140435
 TI Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use
 IN Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.

PA USA

SO U.S. Pat. Appl. Publ., 42 pp.
 CODEN: USXXCO

DT Patent

LA English



FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|---------------|------|----------|-----------------|----------|
| PI | US 2002103242 | A1 | 20020801 | US 2001-21667 | 20011029 |
| | WO 2002060434 | A2 | 20020808 | WO 2001-US49501 | 20011026 |
| | WO 2002060434 | A3 | 20030619 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |

PRAI US 2000-244698P P 20001031

OS MARPAT 137:140435

GI



AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherēin: $Z = \text{CH}_2, \text{CO}$; $R_1 = \text{H}, \text{OH}, \text{halo}, (\text{un})\text{substituted alk(en/yn)yl}, \text{alk(en/yn)yloxy, or aryl; or } R_1 \text{ forms (un)substituted cyclopropane fusion to adjacent C atom; } X, Y = \text{O, S, SO, SO}_2, \text{CH}_2, (\text{un})\text{substituted NH; } n = 1-6; R_4 = (\text{un})\text{substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups} = \text{H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or } R_3R_4 \text{ or } R_4R_5 = (\text{un})\text{substituted 5- or 6-membered heterocyclic ring}]. A list of 29 compds. is claimed, and their prepns. is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with $\text{PhCH}_2\text{O}(\text{CH}_2)_3\text{Br}$ (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alk. hydrolysis (100%), to give title compd. II. PPAR binding assays using human recombinant PPAR are described without data.$

Co-administration of compds. I with a variety of other drug categories, including a no. of specific drugs, is claimed.


IT 163222-33-1, Ezetimibe

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic compns. also contg.; prepns. of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574958 CAPLUS
DN 137:135087
TI Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Velttri, Enrico P.
PA Schering Corporation, USA
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002058734 | A2 | 20020801 | WO 2002-US2013 | 20020125 |
| | WO 2002058734 | A3 | 20030703 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2002147184 | A1 | 20021010 | US 2002-56680 | 20020125 |
| | US 2002192203 | A1 | 20021219 | US 2002-136968 | 20020501 |
| PRAI | US 2001-264275P | P | 20010126 | | |
| | US 2001-264396P | P | 20010126 | | |
| | US 2001-264600P | P | 20010126 | | |
| | US 2001-324123P | P | 20010921 | | |
| | US 2001-323839P | P | 20010921 | | |
| | US 2002-57323 | A3 | 20020125 | | |
| OS | MARPAT 137:135087 | | | | |
| AB | The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor administered in an amt. of 0.1-1000 mg/day; and (b) at least one blood modifier administered in an amt. of 1-1000 mg/day, which can be useful for treating vascular conditions, e.g., diabetes and obesity, and lowering plasma levels of sterols in mammals. A sterol absorption inhibitor is an azetidinone compd. or a .beta.-lactam, while a blood modifier was selected from anticoagulants, antithrombotics, fibrinogen receptor antagonists, platelet aggregation inhibitors, hemorheol. agents, lipoprotein assocd. coagulation inhibitors, Factor VIIa inhibitors, and Factor Xa inhibitors. Prepn. of a sterol inhibitor ezetimibe is described. | | | | |
| IT | 163222-32-0P 163380-15-2P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders) | | | | |
| RN | 163222-32-0 CAPLUS | | | | |

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 163222-33-1P, Ezetimibe 163380-16-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 163380-16-3 CAPLUS


CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574957 CAPLUS
DN 137:135086
TI Combinations of bile acid sequestrant(s) and azetidinone sterol absorption inhibitor(s) and treatments for vascular indications
IN Davis, Harry R.; Kosoglou, Teddy
PA Schering Corporation, USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|---|----------|-----------------|----------|
| WO 2002058733 | A2 | 20020801 | WO 2002-US2010 | 20020125 |
| WO 2002058733 | C2 | 20021121 | | |
| WO 2002058733 | A3 | 20030626 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2003053981 | A1 | 20030320 | US 2002-57534 | 20020125 |
| PRAI US 2001-264600P | P | 20010126 | | |
| US 2001-323842P | P | 20010921 | | |
| OS MARPAT 137:135086 | | | | |
| GI | | | | |



AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT 163222-33-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 163222-32-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:574956 CAPLUS

DN 137:129904

TI Combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases

IN Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard

PA Schering Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2002058732 | A2 | 20020801 | WO 2002-US2009 | 20020125 |
| | WO 2002058732 | A3 | 20030703 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2002151536 | A1 | 20021017 | US 2002-57323 | 20020125 |
| | US 2002192203 | A1 | 20021219 | US 2002-136968 | 20020501 |
| PRAI | US 2001-264396P | P | 20010126 | | |
| | US 2001-323839P | P | 20010921 | | |
| | US 2002-57323 | A3 | 20020125 | | |
| OS | MARPAT 137:129904 | | | | |
| AB | The present invention provides compns., therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (PPAR) activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone 4, croscarmellose sodium 8, sodium lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets contg. a PPAR activator such as ezetimibe. Synthetic prepn. of ezetimibe from fluorophenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of fenofibrate was well tolerated and caused a significant redn. in LDL-C as compared to either drug alone or placebo. | | | | |
| IT | 163222-33-1, Ezetimibe. | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases) | | | | |
| RN | 163222-33-1 CAPLUS | | | | |
| CN | 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry. Rotation (-).




IT 163222-32-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574955 CAPLUS
DN 137:129903
TI Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002058731 | A2 | 20020801 | WO 2002-US1196 | 20020125 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2003069221 | A1 | 20030410 | US 2002-57339 | 20020125 |
| | US 2002192203 | A1 | 20021219 | US 2002-136968 | 20020501 |
| PRAI | US 2001-264275P | P | 20010126 | | |
| | US 2001-264396P | P | 20010126 | | |
| | US 2001-264600P | P | 20010126 | | |
| | US 2001-323842P | P | 20010921 | | |
| | US 2001-323839P | P | 20010921 | | |
| | US 2002-57323 | A3 | 20020125 | | |
| OS | MARPAT | 137:129903 | | | |
| GI | | | | | |




AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prep'd. contg. cardiovascular agents which can be coadministered with formulations contg., e.g., I. The prepn. of I was given.

IT 163222-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phénylmethoxy)phenyl]-, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 163222-33-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:574926 CAPLUS
 DN 137:135094
 TI The use of substituted azetidinone compounds for the treatment of sitosterolemia
 IN Davis, Harry R.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2002058696 | A2 | 20020801 | WO 2002-US1195 | 20020125 |
| | WO 2002058696 | A3 | 20030313 | | |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
 ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
 MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
 SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002169134 A1 20021114 US 2002-57629 20020125

PRAI US 2001-264645P P 20010126

OS MARPAT 137:135094

GI



AB The invention discloses the use of sterol absorption-inhibiting compds., pharmaceutical compns. thereof, therapeutic combinations, and their use in combination with other lipid-lowering agents to treat or prevent sitosterolemia and/or to lower the concn. of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or

preventing vascular disease and coronary events also are provided. The methodol. and compns. of the invention use substituted azetidinone compds., e.g. I (prepn. described).

IT 163222-33-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(azetidinone derivs. for treatment of sitosterolemia)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-[(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 444313-49-9 444313-50-2 444313-51-3

444313-53-5 444313-55-7 444313-57-9

444313-59-1 444313-60-4 444313-61-5

444313-62-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(azetidinone derivs. for treatment of sitosterolemia)

RN 444313-49-9 CAPLUS


CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1

CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 75330-75-5

CMF C24 H36 O5

Absolute stereochemistry.



RN 444313-50-2 CAPLUS


CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,.delta.-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,.beta.R,.delta.R,1S,2S,6S,8S,8aR-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1

CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 81093-37-0

CMF C23 H36 O7

Absolute stereochemistry.




RN 444313-51-3 CAPLUS
CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-rel-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 93957-54-1
CMF C24 H26 F N O4

Relative stereochemistry.
Double bond geometry as shown.




RN 444313-53-5 CAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79902-63-9
CMF C25 H38 O5

Absolute stereochemistry.




RN 444313-55-7 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (.beta.R,.delta.R)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 134523-00-5
CMF C33 H35 F N2 O5

Absolute stereochemistry.




RN 444313-57-9 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 S


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



RN 444313-59-1 CAPLUS


CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-, mixt. with (4R,6S)-6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1

CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 141750-63-2

CMF C25 H22 F N O3

Absolute stereochemistry.

Double bond geometry as shown.




RN 444313-60-4 CAPLUS
CN Cholestyramine, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI)
(CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 11041-12-6
CMF Unspecified
CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 444313-61-5 CAPLUS
CN 1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI)
(CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 182815-44-7
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x . x Cl H

CM 3

CRN 182815-43-6
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x
CCI PMS

CM 4


CRN 182815-42-5
CMF C12 H27 N2 . Cl



● Cl -


CM 5

CRN 92162-19-1
CMF C13 H27 N




CM 6

CRN 107-11-9
CMF C3 H7 N



CM 7

CRN 106-89-8
CMF C3 H5 Cl O




RN 444313-62-6 CAPLUS

CN Colestipol, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 50925-79-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 163222-32-0P 163380-15-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prep. and reaction; azetidinone derivs. for treatment of sitosterolemia)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163380-15-2 CAPLUS


CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:574915 CAPLUS
 DN 137:119671
 TI Combinations of nicotinic acid and derivatives thereof and azetidine sterol absorption inhibitor(s) and treatments for vascular indications
 IN Davis, Harry R.; Kosoglou, Teddy
 PA Schering Corporation, USA
 SO PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------------|--|-----------------|----------|
| PI | WO 2002058685 | A2 | 20020801 | WO 2002-US2004 | 20020125 |
| | WO 2002058685 | A3 | 20030501 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| | US 2002183305 | A1 | 20021205 | US 2002-57646 | 20020125 |
| PRAI | US 2001-264275P | P | 20010126 | | |
| | US 2001-323842P | P | 20010921 | | |
| OS | MARPAT | 137:119671 | | | |
| GI | | | | | |



AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivs. thereof; and (b) at least one substituted azetidinone or substituted beta-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.
 IT 163222-33-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)
 RN 163222-33-1 CAPLUS
 CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-

hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 163222-32-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[3S]-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:487576 CAPLUS

DN 137:41758

TI Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents and in the treatment of atherosclerosis

IN Ghosal, Anima; Zbaida, Shmuel; Chowdhury, Swapan K.; Iannucci, Robert M.; Feng, Wenqing; Alton, Kevin B.; Patrick, James E.; Davis, Harry R.

PA Schering Corporation, USA

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2002050090 | A1 | 20020627 | WO 2001-US49127 | 20011217 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, | | | | |


CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002031049 A5 20020701 AU 2002-31049 20011217
 PRAI US 2000-256875P P 20001220
 WO 2001-US49127 W 20011217
 OS MARPAT 137:41758
 AB Hypocholesterolemic sugar-substituted 2-azetidinone compds. are disclosed, as are a method of lowering cholesterol by administering these compds., pharmaceutical compns. contg. them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.
 IT 438576-93-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction; sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)
 RN 438576-93-3 CAPLUS
 CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, labeled with carbon-14, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 163222-33-1D, glucuronides
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)
 RN 163222-33-1 CAPLUS
 CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



IT 163222-33-1 190448-57-8
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)
 RN 163222-33-1 CAPLUS
 CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-

hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 190448-57-8 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:352625 CAPLUS
DN 129:41376
TI Preparation of sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
IN Yumibe, Nathan P.; Alton, Kevin B.; Van Heek, Margaret; Davis, Harry R.; Vaccaro, Wayne D.
PA Schering Corp., USA
SO U.S., 18 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|----------|
| PI | US 5756470 | A | 19980526 | US 1996-741179 | 19961029 |
| | CN 1205707 | A | 19990120 | CN 1996-199226 | 19961029 |
| | CN 1103780 | B | 20030326 | | |
| PRAI | US 1996-741179 | A | 19961029 | | |
| OS | MARPAT 129:41376 | | | | |
| GI | | | | | |



AB Hypcholesterolemic sugar-substituted 2-azetidinones I ($R = H, OH$, sugar; $R1 = alkylene, cycloalkylene, phenylene, alkenylene$; $G = sugar residue$; $Q = bond, spiro group$; $Ar, Ar1 = aryl$), are disclosed, as well as a method of lowering cholesterol by administering said compds., pharmaceutical compns. contg. them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis. Thus, 1-O-[4-[trans-(3R,4S)-1-(4-fluorophenyl)-2-oxo-3-[(S)-hydroxy-4-fluorophenylpropyl]-4-azetidinyl]phenyl]- β -D-glucuronic acid was prep'd. as anticholesteremic agent 58 % redn. in plasma cholesterol with 3 mg/kg dose in hamsters.

IT 190448-57-8P 190448-58-9P 190448-60-3P


190448-63-6P 190448-79-4P 208259-77-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prep. of sugar substituted azetidinones useful as hypcholesterolemic agents)

RN 190448-57-8 CAPLUS

CN . β -D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190448-58-9 CAPLUS

CN . β -D-Glucopyranosiduronic acid, 4-[(2S,3R)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-1-(4-iodophenyl)-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190448-60-3 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(.beta.-D-glucopyranosyloxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190448-63-6 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190448-79-4 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-hydroxy-3-(4-iodophenyl)propyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208259-77-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[(3-O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 163222-33-1P 190448-83-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sugar substituted azetidinones useful as hypocholesterolemic agents)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 190448-83-0 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-

3-hydroxy-3-(4-iodophenyl)propyl]-4-oxo-2-azetidinyl]phenyl, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis hist

(FILE 'HOME' ENTERED AT 10:50:17 ON 07 SEP 2003)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 07 SEP 2003

L1 STRUCTURE uploaded
L2 2 S L1 SSS SAM
L3 218 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:52:15 ON 07 SEP 2003

L4 16 S L3 AND COMPOSITION
L5 9 S L4 AND (ANTIDIABETIC OR HMG OR PPAR)


=> dis 15 1-9 bib abs hitstr

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:633275 CAPLUS
DN 139:169333
TI Novel anticholesterol compositions and method for using same
IN Dudley, Robert; Liao, Shutsung; Song, Ching
PA USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | US 2003153541 | A1 | 20030814 | US 2002-174934 | 20020619 |
| | WO 9922728 | A1 | 19990514 | WO 1998-US23041 | 19981030 |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 6576660 | B1 | 20030610 | US 2000-530443 | 20000428 |
| | US 2002107233 | A1 | 20020808 | US 2002-72128 | 20020208 |

| | | | | | |
|------|---|----|----------|----------------|----------|
| PRAI | US 2002193357 | A1 | 20021219 | US 2002-137695 | 20020502 |
| | US 1997-63770P | P | 19971031 | | |
| | WO 1998-US23041 | W | 19981030 | | |
| | US 1999-131728P | P | 19990430 | | |
| | US 2000-530443 | A2 | 20000428 | | |
| | US 2000-560236 | A2 | 20000428 | | |
| | US 2001-267493P | P | 20010208 | | |
| | US 2001-288643P | P | 20010503 | | |
| | US 2001-348020P | P | 20011108 | | |
| | US 2002-72128 | A2 | 20020208 | | |
| | US 2002-137695 | A2 | 20020502 | | |
| AB | Disclosed are compns., methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concn., for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The compns., methods, combinations, and kits of the present invention are pharmaceutical compns. comprising at least two of an LXR receptor modulator, a therapeutically effective amt. of a catechin, and/or a therapeutically effective amt. of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibrin acid deriv., niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3 fatty acid. | | | | |
| IT | 163222-33-1, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anticholesterol compns. contg. LXR modulators and lipid regulating agents) | | | | |
| RN | 163222-33-1 CAPLUS | | | | |
| CN | 2-Azétidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry. Rotation (-).



| | | | | | |
|---------|---|--------|---------------------------|-----------------|----------|
| L5 | ANSWER 2 OF 9 | CAPLUS | COPYRIGHT 2003 ACS on STN | | |
| AN | 2003:492702 | CAPLUS | | | |
| DN | 139:47580 | | | | |
| TI | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | | | | |
| IN | Strony, John T. | | | | |
| PA | Schering Corporation, USA | | | | |
| SO | U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 166,942. CODEN: USXXCO | | | | |
| DT | Patent | | | | |
| LA | English | | | | |
| FAN.CNT | 6 | | | | |
| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| PI | US 2003119796 | A1 | 20030626 | US 2002-247085 | 20020919 |
| | US 2003105028 | A1 | 20030605 | US 2002-166942 | 20020611 |

PRAI US 2001-324118P P 20010921
 US 2002-166942 A2 20020611
 US 2000-256875P P 20001220
 US 2001-23295 A2 20011217

OS MARPAT 139:47580

AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one hormone replacement therapy compn.; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5.alpha.-stanols.

IT 163222-32-0P 163222-33-1P 163380-15-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of sterol absorption inhibitors for the combined use with hormone replacement therapy compns. and treatments for vascular conditions in post-menopausal women)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:575765 CAPLUS

DN 137:140435

TI Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use

IN Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.

PA USA

SO U.S. Pat. Appl. Publ., 42 pp.

CODEN: USXXCO

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---------------|------|----------|-----------------|----------|
| PI | US 2002103242 | A1 | 20020801 | US 2001-21667 | 20011029 |
| | WO 2002060434 | A2 | 20020808 | WO 2001-US49501 | 20011026 |
| | WO 2002060434 | A3 | 20030619 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |


PRAI US 2000-244698P P 20001031

OS MARPAT 137:140435

GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (**PPAR**) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other **PPAR** alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH₂, CO; R₁ = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R₁ forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO₂, CH₂, (un)substituted NH; n = 1-6; R₄ = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R₃R₄ or R₄R₅ = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their prepns. is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH₂O(CH₂)₃Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alk. hydrolysis (100%), to give title compd. II. **PPAR** binding assays using human recombinant **PPAR** are described without data. Co-administration of compds. I with a variety of other drug categories, including a no. of specific drugs, is claimed.


IT 163222-33-1, Ezetimibe

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic compns. also contg.; prepns. of benzopyrancarboxylic acid derivs. as **PPAR** agonists for treatment of diabetes and lipid disorders)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:574958 CAPLUS
 DN 137:135087
 TI Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
 IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Velttri, Enrico P.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|---|----------|-----------------|----------|
| PI WO 2002058734 | A2 | 20020801 | WO 2002-US2013 | 20020125 |
| WO 2002058734 | A3 | 20030703 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002147184 | A1 | 20021010 | US 2002-56680 | 20020125 |
| US 2002192203 | A1 | 20021219 | US 2002-136968 | 20020501 |
| PRAI US 2001-264275P | P | 20010126 | | |
| US 2001-264396P | P | 20010126 | | |
| US 2001-264600P | P | 20010126 | | |
| US 2001-324123P | P | 20010921 | | |
| US 2001-323839P | P | 20010921 | | |
| US 2002-57323 | A3 | 20020125 | | |
| OS MARPAT 137:135087 | | | | |
| AB | The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor administered in an amt. of 0.1-1000 mg/day; and (b) at least one blood modifier administered in an amt. of 1-1000 mg/day, which can be useful for treating vascular conditions, e.g., diabetes and obesity, and lowering plasma levels of sterols in mammals. A sterol absorption inhibitor is an azetidinone compd. or a .beta.-lactam, while a blood modifier was selected from anticoagulants, antithrombotics, fibrinogen receptor antagonists, platelet aggregation inhibitors, hemorheol. agents, lipoprotein assocd. coagulation inhibitors, Factor VIIa inhibitors, and Factor Xa inhibitors. Prepn. of a sterol inhibitor ezetimibe is described. | | | |
| IT 163222-32-0P 163380-15-2P | | | | |
| RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | (combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders) | | | |
| RN 163222-32-0 CAPLUS | | | | |

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 163222-33-1P, Ezetimibe 163380-16-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 163380-16-3 CAPLUS


CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574957 CAPLUS
DN 137:135086
TI Combinations of bile acid sequestrant(s) and azetidinone sterol absorption inhibitor(s) and treatments for vascular indications
IN Davis, Harry R.; Kosoglou, Teddy
PA Schering Corporation, USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002058733 | A2 | 20020801 | WO 2002-US2010 | 20020125 |
| | WO 2002058733 | C2 | 20021121 | | |
| | WO 2002058733 | A3 | 20030626 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2003053981 | A1 | 20030320 | US 2002-57534 | 20020125 |
| PRAI | US 2001-264600P | P | 20010126 | | |
| | US 2001-323842P | P | 20010921 | | |
| OS | MARPAT | 137:135086 | | | |
| GI | | | | | |



AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT 163222-33-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 163222-32-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



LS ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:574956 CAPLUS

DN 137:129904

TI Combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases

IN Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard

PA Schering Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|---|----------|
| PI | WO 2002058732 | A2 | 20020801 | WO 2002-US2009 | 20020125 |
| | WO 2002058732 | A3 | 20030703 | | |
| | | | | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | | | | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | |
| | US 2002151536 | A1 | 20021017 | US 2002-57323 | 20020125 |
| | US 2002192203 | A1 | 20021219 | US 2002-136968 | 20020501 |
| PRAI | US 2001-264396P | P | 20010126 | | |
| | US 2001-323839P | P | 20010921 | | |
| | US 2002-57323 | A3 | 20020125 | | |
| OS | MARPAT 137:129904 | | | | |
| AB | The present invention provides compns., therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (PPAR) activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone-4, croscarmellose sodium 8, sodium lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets contg. a PPAR activator such as ezetimibe. Synthetic prepn. of ezetimibe from fluorohenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of fenofibrate was well tolerated and caused a significant redn. in LDL-C as compared to either drug alone or placebo. | | | | |
| IT | 163222-33-1, Ezetimibe. | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases) | | | | |
| RN | 163222-33-1 CAPLUS | | | | |
| CN | 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry. Rotation (-).




IT 163222-32-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574955 CAPLUS
DN 137:129903
TI Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------------|----------|-----------------|----------|
| PI | WO 2002058731 | A2 | 20020801 | WO 2002-US1196 | 20020125 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003069221 | A1 | 20030410 | US 2002-57339 | 20020125 |
| | US 2002192203 | A1 | 20021219 | US 2002-136968 | 20020501 |
| PRAI | US 2001-264275P | P | 20010126 | | |
| | US 2001-264396P | P | 20010126 | | |
| | US 2001-264600P | P | 20010126 | | |
| | US 2001-323842P | P | 20010921 | | |
| | US 2001-323839P | P | 20010921 | | |
| | US 2002-57323 | A3 | 20020125 | | |
| OS | MARPAT | 137:129903 | | | |
| GI | | | | | |



AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prep'd. contg. cardiovascular agents which can be coadministered with formulations contg., e.g., I. The prepn. of I was given.

IT 163222-32-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 163222-33-1P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:574926 CAPLUS
 DN 137:135094
 TI The use of substituted azetidinone compounds for the treatment of sitosterolemia
 IN Davis, Harry R.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------|------|----------|-----------------|----------|
| PI WO 2002058696 | A2 | 20020801 | WO 2002-US1195 | 20020125 |
| | A3 | 20030313 | | |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002169134 A1 20021114 US 2002-57629 20020125

PRAI US 2001-264645P P 20010126

OS MARPAT 137:135094

GI



AB The invention discloses the use of sterol absorption-inhibiting compds., pharmaceutical compns. thereof, therapeutic combinations, and their use in combination with other lipid-lowering agents to treat or prevent sitosterolemia and/or to lower the concn. of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or

preventing vascular disease and coronary events also are provided. The methodol. and compns. of the invention use substituted azetidinone compds., e.g. I (prepn. described).

IT 163222-33-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(azetidinone derivs. for treatment of sitosterolemia)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 444313-49-9 444313-50-2 444313-51-3

444313-53-5 444313-55-7 444313-57-9

444313-59-1 444313-60-4 444313-61-5

444313-62-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(azetidinone derivs. for treatment of sitosterolemia)

RN 444313-49-9 CAPLUS


CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1

CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 75330-75-5

CMF C24 H36 O5

Absolute stereochemistry.



RN 444313-50-2 CAPLUS


CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,.beta.R,.delta.R,1S,2S,6S,8S,8aR)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1

CMF C₂₄H₂₁F₂N₀O₃

Absolute stereochemistry. Rotation (-).




CM 2

CRN 81093-37-0

CMF C₂₃H₃₆O₇

Absolute stereochemistry.




RN 444313-51-3 CAPLUS
CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-rel-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 93957-54-1
CMF C24 H26 F N O4

Relative stereochemistry.
Double bond geometry as shown.




RN 444313-53-5 CAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 79902-63-9
CMF C25 H38 O5

Absolute stereochemistry.




RN 444313-55-7 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (.beta.R,.delta.R)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 134523-00-5
CMF C33 H35 F N2 O5

Absolute stereochemistry.




RN 444313-57-9 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 S


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



RN 444313-59-1 CAPLUS


CN 2-Azetidinone, 1- (4-fluorophenyl)-3- [(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-, mixt. with (4R,6S)-6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1

CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 141750-63-2

CMF C25 H22 F N O3

Absolute stereochemistry.

Double bond geometry as shown.




RN 444313-60-4 CAPLUS
CN Cholestyramine, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI)
(CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 11041-12-6
CMF Unspecified
CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 444313-61-5 CAPLUS
CN 1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI)
(CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 182815-44-7
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x . x Cl H

CM 3

CRN 182815-43-6
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x
CCI PMS

CM 4


CRN 182815-42-5
CMF C12 H27 N2 . Cl



● Cl⁻


CM 5

CRN 92162-19-1
CMF C13 H27 N




CM 6

CRN 107-11-9
CMF C3 H7 N



CM 7

CRN 106-89-8
CMF C3 H5 Cl O




RN 444313-62-6 CAPLUS

CN Colestipol, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 50925-79-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 163222-32-0P 163380-15-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prep. and reaction; azetidinone derivs. for treatment of sitosterolemia)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:574915 CAPLUS

DN 137:119671

TI Combinations of nicotinic acid and derivatives thereof and azetidine sterol absorption inhibitor(s) and treatments for vascular indications

IN Davis, Harry R.; Kosoglou, Teddy

PA Schering Corporation, USA

SO PCT Int. Appl., 131 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002058685 | A2 | 20020801 | WO 2002-US2004 | 20020125 |
| | WO 2002058685 | A3 | 20030501 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2002183305 | A1 | 20021205 | US 2002-57646 | 20020125 |
| PRAI | US 2001-264275P | P | 20010126 | | |
| | US 2001-323842P | P | 20010921 | | |
| OS | MARPAT | 137:119671 | | | |
| GI | | | | | |



AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivs. thereof; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT 163222-33-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-

hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 163222-32-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> dis hist

(FILE 'HOME' ENTERED AT 10:50:17 ON 07 SEP 2003)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 07 SEP 2003

L1 STRUCTURE uploaded
L2 2 S L1 SSS SAM
L3 218 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:52:15 ON 07 SEP 2003

L4 16 S L3 AND COMPOSITION
L5 9 S L4 AND (ANTIDIABETIC OR HMG OR PPAR)